Skip to content

Abstract B107: Peptide-delivered low dose IL-2 reprograms pancreatic cancer immunity to improve survival

Sep 2026 · Cancer Research · 0 citations

Abstract

Metastatic pancreatic cancer (PC) has a dismal 5-year survival rate of 2% due to limited chemotherapy, lack of immunotherapy options, and high drug resistance. The tumor-immune microenvironment (TIME) in PC, marked by dense desmoplasia, inactive anti-cancer T-cells, and immunosuppressive regulatory T-cells (Tregs), hinders immunotherapy responses. Novel approaches are needed to overcome these barriers and activate anti-tumor T-cell responses. Interleukin-2 (IL-2), a dual-function cytokine, promotes T-cell proliferation at high doses but induces immunosuppression at low doses. High-dose IL-2 enhances cytotoxic T-cell activity and suppresses Tregs, but its severe toxicities, including capillary leak syndrome (CLS), limit its use. To address these challenges, iRGD—a tumor-targeting CendR peptide currently in Phase 2 trials for metastatic pancreatic cancer—enhances chemotherapy delivery by binding tumor-specific integrins and NRP-1. We hypothesized that iRGD could similarly deliver low-dose (LD) IL-2 into pancreatic tumors, concentrating it within the tumor microenvironment to activate CD8+ T cells, suppress tumor growth, and improve survival while minimizing systemic toxicity. In orthotopic KPC mouse models, iRGD combined with LD IL-2 significantly reduced tumor burden and improved survival compared to IL-2 alone, while avoiding systemic toxicities such as capillary leak syndrome and cachexia. Our studies revealed that the combination treatment selectively enhanced CD8+ T cell cytotoxic function, evidenced by increased STAT5 phosphorylation, Granzyme B release, and Caspase-3– mediated apoptosis, without broadly expanding CD4+ T cells or Tregs. The therapeutic effect was abrogated by CD8 depletion, confirming its dependence on cytotoxic T cell activity. Patient-derived PDAC slice cultures further validated increased cytotoxic responses with Certepetide + IL-2 treatment. iRGD-guided delivery of low-dose IL-2 reprograms the tumor immune microenvironment, enhancing anti-tumor immunity while mitigating systemic toxicity. This strategy represents a promising translational approach for pancreatic cancer immunotherapy. In Hwan Park, Gregory Botta, Shawn Abeynaike, Jonathan Cho, Ashley Martinez, Tridu Huyhn, Daisuke Nishizaki, Charles Jurisaga. Peptide-delivered low dose IL-2 reprograms pancreatic cancer immunity to improve survival [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B107.

View source

Similar papers

Sep 2026

Abstract B075: Harnessing Tumor-Penetrating Peptides to Modulate the Pancreatic Tumor Immune Microenvironment

Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 13% and remains largely resistant to immunotherapy because its dense fibrotic stroma restricts drug penetration, and its immunosuppressive tumor microenvironment (TME) limits anti-tumor immunity. Novel strategies are urgently needed t...

Shawn A. Abeynaike, In Hwan Park, Ashley Martinez et al. · 0 citations
Sep 2026

Abstract B090: Defining The Immune Mechanisms Required For iRGD-guided Low Dose IL-2 Therapy in Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PCAD) remains one of the deadliest cancers with minimal treatment options, highlighting the need for more effective immunotherapeutic strategies capable of overcoming its highly immunosuppressive tumor microenvironment. Tumor penetrating peptides such as iRGD enhance the delivery and...

M. Harari, In Hwan Park, Shawn A. Abeynaike et al. · 0 citations
Sep 2026

Abstract B108: CXCR4 inhibition reprograms immune checkpoint networks and enhances anti-tumor immunity in patient-derived pancreatic cancer organoid–PBMC co-cultures

A patient-specific ex vivo organoid model is developed to define CXCL12/CXCR4-mediated immune regulation and identify additional cellular and molecular targets to enhance antitumor efficacy and demonstrate that CXCR4 inhibition enhances immune-cell infiltration and activation, modulates checkpoint expression, and promo...

I. Pellicciotta, G. Manji, A. Raufi et al. · 0 citations
Sep 2026

FasL-mediated death of activated intratumoral T cells drives secondary resistance to cancer immunotherapy.

Cancer progression following an initial response to immunotherapy (secondary resistance; 2°R) is a major and poorly understood problem. We treated mice bearing B16 melanoma with a combination of a regulatory T cell (Treg) depleting, non-IL-2 blocking antibody (anti-CD25NIB) and an autologous cancer cell vaccine (GVAX)....

Chen Qing, E. Ghorani, K. Foster et al. · 0 citations
Review Open access Sep 2026

Adoptive cell therapy in lung cancer: progress, challenges, and prospects

The current progress in cell therapy for lung cancer is summarized, key challenges are analyzed, and potential solutions are proposed.

Jing-Yi-Li-Jing-Yi Li, Chan Tong, Yong-Chang Chen et al. · 0 citations
Open access Sep 2026

γδ T cells modulate anti-tumor immunity in small cell lung cancer.

It is demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate can sensitize SCLC cells to γδ T cell-mediated killing.

Jin Ng, Yue You, Tina Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.